Effectiveness of Direct-Acting Antiviral Therapy in Patients with Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in Routine Clinical Care: A Multicenter Study

H. Nina Kim, Robin M. Nance, Jessica S. Williams-Nguyen, J. A. Chris Delaney, Heidi M. Crane, Edward R. Cachay, Jeffrey Martin, W. Christopher Mathews, Geetanjali Chander, Ricardo Franco, Christopher B. Hurt, Elvin H. Geng, Benigno Rodriguez, Richard D. Moore, Michael S. Saag, Mari M. Kitahata

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

Background Direct-acting antiviral (DAA) therapy have been shown to be highly successful in clinical trials and observational studies, but less is known about treatment success in patients with a high burden of comorbid conditions, including mental health and substance use disorders. We evaluated DAA effectiveness across a broad spectrum of patients with human immunodeficiency virus (HIV)-hepatitis C virus (HCV) coinfection in routine clinical care, including those with psychosocial comorbid conditions. Methods The primary end point was sustained virologic response (SVR), defined as HCV RNA not detected or <25 IU/mL ≥10 weeks after treatment. We calculated SVR rates and 95% confidence intervals (CIs) in a modified intent-to-treat analysis. We repeated this analysis after multiply imputing missing SVR values. Results Among 642 DAA-treated patients, 536 had SVR assessments. The median age was 55 years; 79% were men, 59% black, and 32% white. Cirrhosis (fibrosis-4 index>3.25) was present in 24%, and 17% were interferon treatment experienced; 96% had genotype 1 infection and 432 (81%) had received ledipasvir-sofosbuvir. SVR occurred in 96.5% (95% CI, 94.5%-97.9%). Patients who were black, treatment experienced, or cirrhotic all had SVR rates >95%. Patients with depression and/or anxiety, psychotic disorder, illicit drug use, or alcohol use disorder also had high SVR rates, ranging from 95.4% to 96.8%. The only factor associated with lower SVR rate was early discontinuation (77.8%; 95% CI, 52.4%-93.6%). Similar results were seen in multiply imputed data sets. Conclusions Our study represents a large multicenter examination of DAA therapy in HIV/HCV-coinfected patients. The broad treatment success we observed across this diverse group of patients with significant comorbid conditions is highly affirming and argues for widespread implementation of DAA therapy.

Original languageEnglish
JournalOpen Forum Infectious Diseases
Volume6
Issue number4
DOIs
StatePublished - Mar 23 2019
Externally publishedYes

Keywords

  • HIV
  • direct-acting antiviral
  • hepatitis C virus

Fingerprint Dive into the research topics of 'Effectiveness of Direct-Acting Antiviral Therapy in Patients with Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in Routine Clinical Care: A Multicenter Study'. Together they form a unique fingerprint.

  • Cite this

    Kim, H. N., Nance, R. M., Williams-Nguyen, J. S., Chris Delaney, J. A., Crane, H. M., Cachay, E. R., Martin, J., Mathews, W. C., Chander, G., Franco, R., Hurt, C. B., Geng, E. H., Rodriguez, B., Moore, R. D., Saag, M. S., & Kitahata, M. M. (2019). Effectiveness of Direct-Acting Antiviral Therapy in Patients with Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in Routine Clinical Care: A Multicenter Study. Open Forum Infectious Diseases, 6(4). https://doi.org/10.1093/ofid/ofz100